Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer
Von Pawel J.,Asklepios Fachkliniken Munich Gauting |
Harvey J.H.,Alabama Oncology |
Spigel D.R.,Sarah Cannon Research Institute |
Dediu M.,Institute Of Oncology Prof Dr Alexandru Trestioreanu |
And 5 more authors.
Clinical Lung Cancer | Year: 2014
Background This phase II study examined the efficacy of mapatumumab in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer (NSCLC). Patients and Methods Patients with stage IIIB or stage IV advanced primary NSCLC were randomly assigned (1:1:1) to receive up to 6 courses of standard-dose paclitaxel and carboplatin or a combination of paclitaxel, carboplatin, and mapatumumab (10 mg/kg or 30 mg/kg). Primary efficacy end points were overall response rate and median progression-free survival (PFS). Secondary efficacy end points included disease control rate, overall survival (OS), time to response, and duration of response. Exploratory studies included evaluation of historical biopsy materials for TRAIL-R1 expression by immunohistochemical analysis and serum levels of M30, a marker of apoptosis, before and after the first 2 doses of mapatumumab. Safety parameters, including adverse events (AEs), laboratory tests, and immunogenicity, were assessed. Results The majority of patients had stage IV disease (79%) and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 (58%); baseline characteristics were similar across treatment arms. No improvements in response or disease control rates, PFS, or OS were gained from the addition of mapatumumab. Adverse events in the mapatumumab arms were generally consistent with toxicities seen in the carboplatin and paclitaxel control arm. Levels of M30 were highly variable, and consistent patterns were not seen across treatment arms. Conclusion This study showed no clinical benefit from adding mapatumumab to carboplatin and paclitaxel in unselected patients with NSCLC. The combination was generally well tolerated. The possibility of subgroups sensitive to mapatumumab is discussed. © 2014 Elsevier Inc. All rights reserved. Source
Chiappori A.A.,H. Lee Moffitt Cancer Center and Research Institute |
Kolevska T.,Kaiser Permanente |
Spigel D.R.,Sarah Cannon Research Institute |
Hager S.,Cancer Care Associates of Fresno Medical Group |
And 9 more authors.
Annals of Oncology | Year: 2015
Imetelstat, a novel telomerase inhibitor, failed to improve significantly median PFS and OS as maintenance therapy (±bevacizumab) in advanced NSCLC. Telomere length (TL) biomarker results were consistent with the hypothesis that telomerase inhibition is of greater benefit to patients with tumors possessing shorter telomeres; the patients with shorter TL had a trend toward longer median PFS and OS. © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. Source
Manegold C.,University of Mannheim |
Vansteenkiste J.,University Hospital Gasthuisberg |
Cardenal F.,Institute Catala dOncologia |
Schuette W.,Krankenhaus Martha Maria Halle Dolau |
And 5 more authors.
Investigational New Drugs | Year: 2013
Summary: Introduction This multicenter, open-label, phase II study was carried out to compare the efficacy and safety of cilengitide (EMD 121974), a selective inhibitor of the cell-surface integrins αVβ3 and αVβ5, with that of docetaxel in patients with advanced non-small-cell lung cancer (NSCLC). Methods Patients (n = 140) with advanced NSCLC who had failed first-line chemotherapy were randomized to cilengitide 240, 400, or 600 mg/m2 twice weekly, or docetaxel 75 mg/m2 once every 3 weeks for eight cycles. Non-progressing patients could continue cilengitide for up to 1 year. The primary endpoint was progression-free survival (PFS). No statistical tests were performed since the study was exploratory in nature and the number of patients enrolled was relatively small. Results Median PFS was 54, 63, 63, and 67 days for cilengitide 240, 400, and 600 mg/m2, and docetaxel 75 mg/m2, respectively. One-year survival rates were 13 %, 13 %, 29 %, and 27 %, respectively. The response rate (partial response only) with docetaxel was 15 %. No responses were reported in any cilengitide arm. The most frequent grade 3/4 treatment-related adverse events in the docetaxel group were leukopenia and neutropenia (experienced by 13 % of patients). Hematologic toxicity of this severity did not occur in cilengitide-treated patients. Conclusion With the highest dose of cilengitide (600 mg/m2), median PFS and 1-year survival were similar to those in patients treated with docetaxel 75 mg/m2 and there were fewer grade 3/4 treatment-related adverse events. © 2012 The Author(s). Source
Weber N.,Asklepios Fachkliniken Munich Gauting
Pneumologe | Year: 2012
Management of respiratory allergies comprises prevention of exposure to allergens, pharmacologic treatment with controllers and relievers and specific immunotherapy (SIT). Omalizumab is an immunomodulating agent the use of which is confined to asthma which cannot otherwise be treated. Avoiding exposure to tobacco smoke is easily implemented and effective. Controlling airway inflammation primarily by inhaled glucocorticosteroids is of high significance and is already to be applied at step 2 in a 5-step treatment. In managing allergic rhinitis topical glucocorticosteroids are likewise of high significance. The SIT as a causal approach is proven in either form of application in treatment of rhinitis but the efficacy in asthma is still limited. Concerning sublingual immunotherapy (SLIT) in treatment of asthma a conclusive appraisal is not yet permitted. © Springer-Verlag Berlin Heidelberg 2012. Source
Staab-Weijnitz C.A.,Helmholtz Center Munich |
Fernandez I.E.,Helmholtz Center Munich |
Knuppel L.,Helmholtz Center Munich |
Maul J.,Helmholtz Center Munich |
And 11 more authors.
American Journal of Respiratory and Critical Care Medicine | Year: 2015
Rationale: Increased abundance and stiffness of the extracellular matrix, in particular collagens, is a hallmark of idiopathic pulmonary fibrosis (IPF). FK506-binding protein 10 (FKBP10) is a collagen chaperone, mutations of which have been indicated in the reduction of extracellular matrix stiffness (e.g., in osteogenesis imperfecta). Objectives: To assess the expression and function of FKBP10 in IPF. Methods: We assessed FKBP10 expression in bleomycin-induced lung fibrosis (using quantitative reverse transcriptase-polymerase chain reaction, Western blot, and immunofluorescence), analyzed microarray data from 99 patients with IPF and 43 control subjects from a U.S. cohort, and performed Western blot analysis from 6 patients with IPF and 5 control subjects from a German cohort. Subcellular localization of FKBP10 was assessed by immunofluorescent stainings. The expression and function of FKBP10, as well as its regulation by endoplasmic reticulum stress or transforming growth factor-β1, was analyzed by small interfering RNA-mediated loss-of-function experiments, quantitative reverse transcriptase-polymerase chain reaction, Western blot, and quantification of secreted collagens in the lung and in primary human lung fibroblasts (phLF). Effects on collagen secretion were compared with those of the drugs nintedanib and pirfenidone, recently approved for IPF. Measurements and Main Results: FKBP10 expression was up-regulated in bleomycin-induced lung fibrosis and IPF. Immunofluorescent stainings demonstrated localization to interstitial (myo)fibroblasts and CD68+ macrophages. Transforming growth factor-β1, but not endoplasmic reticulum stress, induced FKBP10 expression in phLF. The small interfering RNA-mediated knockdown of FKBP10 attenuated expression of profibrotic mediators and effectors, including collagens I and V and α-smooth muscle actin, on the transcript and protein level. Importantly, loss of FKBP10 expression significantly suppressed collagen secretion by phLF. Conclusions: FKBP10 might be a novel drug target for IPF. Copyright © 2015 by the American Thoracic Society. Source